Cell-Selective Delivery of RIBOTACs via an Anti-EGFR Nanobody for Pancreatic Cancer Treatment
This study develops a dual-targeting, bioresponsive nanobody-RIBOTAC for pancreatic ductal adenocarcinoma. An EGFR-targeting nanobody-Fc fusion and a cathepsin B-responsive linker …
Tianli Luo